Better Rap for Bilirubin

Frontlines | Better Rap for Bilirubin Erica P. Johnson The yellow bile pigment bilirubin has a bad reputation. The normal end-product of hemoglobin breakdown, in excess it causes jaundice, lethargy, seizures, and death. Yet, people with only slightly elevated levels are less prone to heart disease. Neuroscientist Solomon Snyder and colleagues at Johns Hopkins Medical School in Baltimore discovered why the body makes bilirubin at all, when its immediate precursor, biliverdin, is easily excr

Written byRicki Lewis
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

The yellow bile pigment bilirubin has a bad reputation. The normal end-product of hemoglobin breakdown, in excess it causes jaundice, lethargy, seizures, and death. Yet, people with only slightly elevated levels are less prone to heart disease. Neuroscientist Solomon Snyder and colleagues at Johns Hopkins Medical School in Baltimore discovered why the body makes bilirubin at all, when its immediate precursor, biliverdin, is easily excreted: Bile is a powerful, if fleeting, antioxidant (D.E. Barañano et al., "Biliverdin reductase: A major physiologic cytoprotectant," Proc Natl Acad Sci, 99:16093-8, Dec. 10, 2002).

Using RNAi to block the enzyme that interconverts biliverdin and bilirubin doomed the human and rat cells exposed to oxygen radicals. But restoring enzyme function enabled the cells to withstand a 10,000-fold increase in peroxide concentration. Snyder explains that the bilirubin is continuously recycled to keep it functional. "As soon as a molecule of bilirubin is consumed, it is converted ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies